10 completed. 10 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
| Phase 1 | 1 | Completed 1 |
Follow Midomafetamine: new trials by email Literature Review of Midomafetamine trials Research Report on Midomafetamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study Midomafetamine HCl - PTSD | Phase 2 | Completed | MAPS Europe B.V. | 21 | 2020-06-24 | 2025-01-28 |
| Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada) Midomafetamine HCl, Manualized therapy - Posttraumatic Stress Disorder | Phase 2 | Completed | Resilient Pharmaceuticals | 4 | 2018-03-13 | 2025-06-10 |
| Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD Midomafetamine, Manualized therapy - PTSD | Phase 2 | Completed | Resilient Pharmaceuticals | 38 | 2017-11-16 | 2025-06-05 |
| MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD MDMA, CBCT, Therapy - Posttraumatic Stress Disorder | Phase 1 / Phase 2 | Completed | Resilient Pharmaceuticals | 12 | 2016-07-03 | 2025-06-04 |
| MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness Midomafetamine HCl, Placebo, Therapy - Anxiety | Phase 2 | Completed | Resilient Pharmaceuticals | 18 | 2015-05-14 | 2025-06-05 |
| Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl - Posttraumatic Stress Disorder | Phase 2 | Completed | Resilient Pharmaceuticals | 29 | 2013-05-13 | 2025-06-05 |
| Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD Active Placebo Dose MDMA-assisted therapy (25 mg), Full Dose MDMA-assisted therapy (125 mg), Open-Label Full Dose MDMA-assisted therapy (125 mg) - Posttraumatic Stress Disorder (PTSD) | Phase 2 | Completed | Resilient Pharmaceuticals | 10 | 2013-01-17 | 2025-06-06 |
| Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial Midomafetamine, Therapy - Posttraumatic Stress Disorder | Phase 2 | Completed | Resilient Pharmaceuticals | 3 | 2010-12-15 | 2024-01-24 |
| Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder Low dose MDMA-assisted therapy, Medium dose MDMA-assisted therapy, Full dose MDMA-assisted therapy - Posttraumatic Stress Disorder | Phase 2 | Completed | Resilient Pharmaceuticals | 26 | 2010-11-10 | 2025-06-05 |
| MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder Midomafetamine HCl, Lactose placebo pill, Therapy - Posttraumatic Stress Disorder | Phase 2 | Completed | Resilient Pharmaceuticals | 23 | 2004-03-12 | 2025-06-06 |
Stress Disorders, Post-Traumatic (9) · Anxiety Disorders (1) · Depression (1)
Resilient Pharmaceuticals (9) · MAPS Europe B.V. (1)
United States (7) · Canada (1) · Czechia (1) · Germany (1) · Israel (1) · Netherlands (1) · Norway (1) · United Kingdom (1)
Michael C Mithoefer, MD (3) · Michael Mithoefer, MD (2) · Michael Mithoefer (1) · Moshe Kotler (1) · Philip Wolfson, MD (1) · Prof. Dr. Eric Vermetten, MD (1)
PMID 31065731, PMID 31572236, PMID 32500209, PMID 20643699, PMID 23172889, PMID 29728331, PMID 33235285, PMID 36405923, PMID 38174611